EW: יחס שווי שוק להכנסות Edwards

Edwards Lifesciences dominates the cardiology sector thanks to its unique minimally invasive valve replacement methods. The price-to-sales ratio visualizes this premium valuation, where the 9.10 level reflects the current magnitude of market expectations. Patents and an evidence-based foundation protect the issuer's position from competitive pressure, while a strategy of acquiring small startups ensures organic growth through the integration of new developments.

The P/S ratio determines the market value of one dollar of sales, allowing for an assessment of the premium paid for an asset relative to its revenue. By analyzing the divergence of the P/S from its historical average at the current value of 9.10, an investor compares the multiple with the business uniqueness of Edwards Lifesciences (EW), whose dominance in the minimally invasive valve segment justifies a premium valuation due to a lack of technological alternatives.